BR 790
Alternative Names: BR-790Latest Information Update: 23 Aug 2022
At a glance
- Originator Jiangxi Qingfeng Pharmaceutical
- Developer Shanghai Gopherwood Biotech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 18 Aug 2022 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (PO) (NCT05505877)
- 18 May 2021 Preclinical trials in Solid tumours in China (PO) prior to May 2021
- 18 May 2021 Jiangxi Qingfeng Pharmaceutical plans a phase I trial for Solid tumour (Monotherapy, Late-stage disease, Second-line therapy or greater) (PO, Tablet) in June 2021 (NCT04891653)